Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease

Robert A Hauser1 Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL, USACorrespondence[email protected]

Aaron Ellenbogen2 Quest Research Institute, Bingham Farms, MI, USA

Sarita Khanna3 Impax Laboratories, Inc., Hayward, CA, USA

Suneel Gupta3 Impax Laboratories, Inc., Hayward, CA, USA

Nishit B Modi3 Impax Laboratories, Inc., Hayward, CA, USA

Pages 839-845 | Published online: 22 Mar 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Impax Laboratories, IncRytary (carbidopa and levodopa) extended-release capsules: full prescribing information2016 Available from: http://documents.impaxlabs.com/rytary/pi.pdfAccessed August 21, 2017
Google Scholar
MitturAGuptaSModiNBPharmacokinetics of Rytary®, an extended-release capsule formulation of carbidopa-levodopaClin Pharmacokinet2017569999101428236251
PubMed Web of Science ®Google Scholar
HauserRAHsuAKellSExtended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trialLancet Neurol201312434635623485610
PubMed Web of Science ®Google Scholar
WatersCHNausiedaPDzyakLLong-term treatment with extended-release carbidopa-levodopa (IPX066) in early and advanced Parkinson’s disease: a 9-month open-label extension trialCNS Drugs201529434135025895021
PubMed Web of Science ®Google Scholar
PahwaRLyonsKEHauserRARandomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s diseaseParkinsonism Relat Disord201420214214824055014
PubMed Web of Science ®Google Scholar
StocchiFHsuAKhannaSComparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patientsParkinsonism Relat Disord201420121335134025306200
PubMed Web of Science ®Google Scholar
HsuAYaoHMGuptaSModiNBComparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®)J Clin Pharmacol2015559995100325855267
PubMed Web of Science ®Google Scholar
HauserRAEllenbogenALMetmanLVCrossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s diseaseMov Disord201126122246225221755537
PubMed Web of Science ®Google Scholar
ContinMRivaRMartinelliPAlbaniFBaruzziARelationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up studyClin Neuropharmacol19972054094189331517
PubMed Web of Science ®Google Scholar
ContinMRivaRMartinelliPAlbaniFBaruzziAEffect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patientsEur J Clin Pharmacol19985443033089696954
PubMed Web of Science ®Google Scholar
ContinMRivaRMartinelliPResponse to a standard oral levodopa test in parkinsonian patients with and without motor fluctuationsClin Neuropharmacol199013119282306746
PubMed Web of Science ®Google Scholar
GancherSTNuttJGWoodwardWResponse to brief levodopa infusions in parkinsonian patients with and without motor fluctuationsNeurology19883857127163362366
PubMed Web of Science ®Google Scholar
NuttJGCarterJHVan HoutenLWoodwardWRShort- and long-duration responses to levodopa during the first year of levodopa therapyAnn Neurol19974233493559307256
PubMed Web of Science ®Google Scholar
RascolODefining a minimal clinically relevant difference for the unified Parkinson’s rating scale: an important but still unmet needMov Disord20062181059106116673409
PubMed Web of Science ®Google Scholar
ShulmanLMGruber-BaldiniALAndersonKEFishmanPSReichSGWeinerWJThe clinically important difference on the Unified Parkinson’s Disease Rating ScaleArch Neurol2010671647020065131
PubMedGoogle Scholar
BrodskyMAParkBSNuttJGEffects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson diseaseArch Neurol2010671273220065126
PubMedGoogle Scholar
HauserRAGordonMFMizunoYMinimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended releaseParkinsons Dis2014201446713124800101
PubMed Web of Science ®Google Scholar
SchragASampaioCCounsellNPoeweWMinimal clinically important change on the Unified Parkinson’s Disease Rating ScaleMov Disord20062181200120716673410
PubMed Web of Science ®Google Scholar
HauserRAAuingerPParkinson Study GroupDetermination of minimal clinically important change in early and advanced Parkinson’s diseaseMov Disord201126581381821437987
PubMed Web of Science ®Google Scholar
HauserRAFriedlanderJZesiewiczTAA home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesiaClin Neuropharmacol2000232758110803796
PubMed Web of Science ®Google Scholar
LewittPAEllenbogenAChenDActively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuationsClin Neuropharmacol201235310311022406623
PubMed Web of Science ®Google Scholar
MerimsDDjaldettiRMelamedEWaiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuationsClin Neuropharmacol200326419619812897640
PubMed Web of Science ®Google Scholar
NelsonMVBerchouRCLeWittPAKaretiDGallowayMPPharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson’s diseaseNeurology199040170742296385
PubMed Web of Science ®Google Scholar
LeWittPAJenningsDLyonsKEPharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategiesMov Disord20092491319132419412946
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date